OnBioVChttp://onbiovc.comYour Source for BioScience Venture Capital Dataenhttp://wordpress.org/?v=2.6.5onbiovc/NCeLhttp://feedburner.google.comSeptember 2009 OnBioVC | Trend Analysis Now Availablehttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/BJ5SCBFk6lk/UncategorizedarubensteinTue, 03 Nov 2009 21:47:41 PSThttp://onbiovc.com/?p=1485Hot off the press! The September 2009 OnBioVC | Trend Analysis study is now available for download [HERE]. Over $465M flowed into early-stage biopharma, diagnostic and device companies in the ninth month of 2009 and over $4,806M year-to-date! If you find the information in OnBioVC to be of value kindly forward on to colleagues who you believe would likewise be interested in the content. Thank you!
________________________________________________________________________

Sign up [HERE] for FREE Subscription to ‘Pharmaceutical Executive’ and ‘Life Science Leader’ Magazines (and other journals too!)

]]>Hot off the press! The September 2009 OnBioVC | Trend Analysis study is now available for download [HERE]. Over $465M flowed into early-stage biopharma, diagnostic and device companies in the ninth month of 2009 and over $4,806M year-to-date! If you find the information in OnBioVC to be of value kindly forward on to colleagues who [...]http://onbiovc.com/september-2009-onbiovc-trend-analysis-now-available/feed/http://onbiovc.com/september-2009-onbiovc-trend-analysis-now-available/Celladon, Inc.: Series C $21.8Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/Qobz3atL5oA/I - Series CQ - 3Q09R - WESTX - CardiologyX - Gene TherapyXX - CAarubensteinMon, 02 Nov 2009 14:22:55 PSThttp://onbiovc.com/?p=1480Celladon (La Jolla, CA) a clinical-stage company focused on gene therapy for congestive heart failure, closed a $21.8M Series C financing. Participants include Enterprise Partners Venture Capital, Venrock and Johnson & Johnson Dev Corp.

]]>Celladon (La Jolla, CA) a clinical-stage company focused on gene therapy for congestive heart failure, closed a $21.8M Series C financing. Participants include Enterprise Partners Venture Capital, Venrock and Johnson & Johnson Dev Corp.http://onbiovc.com/celladon-inc-series-c-218m/feed/http://onbiovc.com/celladon-inc-series-c-218m/Quanta Fluid Solutions, Ltd.: Series A $14.3Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/bR0bLMIwj_Q/I - Series AQ - 3Q09R - INTERNATIONALX - Device (Renal)arubensteinMon, 02 Nov 2009 13:47:24 PSThttp://onbiovc.com/?p=1478Quanta Fluid Solutions (United Kingdom) a development-stage medical device company focused on haemodialysis systems for acute renal failure, has closed a $14.3M Series A financing. Participants include NBGI Ventures, Seroba Kernel Life Sciences, Wellington Partners Venture Capital and Brains-To-Ventures.

]]>Quanta Fluid Solutions (United Kingdom) a development-stage medical device company focused on haemodialysis systems for acute renal failure, has closed a $14.3M Series A financing. Participants include NBGI Ventures, Seroba Kernel Life Sciences, Wellington Partners Venture Capital and Brains-To-Ventures.http://onbiovc.com/quanta-fluid-solutions-ltd-series-a-143m/feed/http://onbiovc.com/quanta-fluid-solutions-ltd-series-a-143m/Calypso Medical Technologies, Inc.: Series E $50Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/INzhuuwnjJg/I - Series EQ - 3Q09R - NORTH WESTX - Device (Imaging)X - Device (Radiotherapy)XX - WAarubensteinMon, 02 Nov 2009 13:29:58 PSThttp://onbiovc.com/?p=1475Calypso Medical Technologies (Seattle, WA) a commercial-stage medical device company focused on implantable sensor electromagnetic transponders, to accurately and continuously pinpoint the location of tumors in real-time during radiation therapy delivery, closed a $50M Series E financing. Participants include Skyline Ventures, Frazier Healthcare Ventures, Bay City Capital and InterWest Partners.

]]>Calypso Medical Technologies (Seattle, WA) a commercial-stage medical device company focused on implantable sensor electromagnetic transponders, to accurately and continuously pinpoint the location of tumors in real-time during radiation therapy delivery, closed a $50M Series E financing. Participants include Skyline Ventures, Frazier Healthcare Ventures, Bay City Capital and InterWest Partners.http://onbiovc.com/calypso-medical-technologies-inc-series-e-50m/feed/http://onbiovc.com/calypso-medical-technologies-inc-series-e-50m/NextBio, Inc.: Series C $8Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/q2e2Oi_UVTs/I - Series CQ - 3Q09R - WESTX - BioinformaticsXX - CAarubensteinMon, 02 Nov 2009 13:27:19 PSThttp://onbiovc.com/?p=1473NextBio (Cupertino, CA) a commercial-stage bioinformatics and competitive intelligence bioscience search engine, closed a $8M Series C financing. Participants include Newbury Ventures.

]]>NextBio (Cupertino, CA) a commercial-stage bioinformatics and competitive intelligence bioscience search engine, closed a $8M Series C financing. Participants include Newbury Ventures.http://onbiovc.com/nextbio-inc-series-c-8m/feed/http://onbiovc.com/nextbio-inc-series-c-8m/Seaside Therapeutics, LLC: Series A $30Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/O90s0ZE4SSg/I - Series AQ - 3Q09R - NORTH EASTX - AutismX - FragileX SyndromeXX - MAarubensteinMon, 02 Nov 2009 13:24:49 PSThttp://onbiovc.com/?p=1471Seaside Therapeutics (Cambridge, MA) a clinical-stage biopharmaceutical company focused on autism and Fragile X syndrome, closed a $30M Series A financing. Participants were not identified.

]]>Seaside Therapeutics (Cambridge, MA) a clinical-stage biopharmaceutical company focused on autism and Fragile X syndrome, closed a $30M Series A financing. Participants were not identified.http://onbiovc.com/seaside-therapeutics-llc-series-a-30m/feed/http://onbiovc.com/seaside-therapeutics-llc-series-a-30m/Juvaris BioTherapeutics, Inc.: Series B $12.5M*http://feedproxy.google.com/~r/onbiovc/NCeL/~3/IXazOJHUjQQ/I - Series BQ - 3Q09R - WESTX - InfluenzaX - LeukemiaX - VaccinesX - VeterinaryXX - CAarubensteinMon, 02 Nov 2009 13:22:46 PSThttp://onbiovc.com/?p=1469Juvaris BioTherapeutics (Pleasanton, CA) a clinical-stage biopharma company focused on adjuvanted vaccines for seasonal flu and immunotherapeutics for Leukemia and animal health, closed a $12.5M Series B financing. Participants include SV Life Sciences and Kleiner Perkins Caufield & Byers.

*Estimated first close of round

]]>Juvaris BioTherapeutics (Pleasanton, CA) a clinical-stage biopharma company focused on adjuvanted vaccines for seasonal flu and immunotherapeutics for Leukemia and animal health, closed a $12.5M Series B financing. Participants include SV Life Sciences and Kleiner Perkins Caufield & Byers. *Estimated first close of roundhttp://onbiovc.com/juvaris-biotherapeutics-inc-series-b-125m/feed/http://onbiovc.com/juvaris-biotherapeutics-inc-series-b-125m/PharmAbcine, Ltd.: Series A $6Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/TpeuF1n1CQI/I - Series AQ - 3Q09R - INTERNATIONALX - AntibodyX - InflammationX - OncologyarubensteinMon, 02 Nov 2009 13:19:58 PSThttp://onbiovc.com/?p=1467PharmAbcine (South Korea) a development-stage biopharma company focused on the development of monoclonal antibodies for cancer and inflammatory disease, closed a $6M Series A financing. Participants include OrbiMed, Novartis Venture Fund, Green Cross, Tong Yang Venture Capital and Saehan Venture Fund.

]]>PharmAbcine (South Korea) a development-stage biopharma company focused on the development of monoclonal antibodies for cancer and inflammatory disease, closed a $6M Series A financing. Participants include OrbiMed, Novartis Venture Fund, Green Cross, Tong Yang Venture Capital and Saehan Venture Fund.http://onbiovc.com/pharmabcine-ltd-series-a-6m/feed/http://onbiovc.com/pharmabcine-ltd-series-a-6m/Virtual Ports, Ltd.: Series A $2.6Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/sotkTf8LoJg/I - Series AQ - 3Q09R - INTERNATIONALX - Device (Endoscopy)arubensteinMon, 02 Nov 2009 13:15:05 PSThttp://onbiovc.com/?p=1465Virtual Ports (Israel) a commercial-stage medical device company focused on an internal retractor for laproscopic procedures and other endoscopic surgical tools, closed a $2.6M Series A financing. Participants include Virginia Life Science Investments and Skywalker Ventures.

]]>Virtual Ports (Israel) a commercial-stage medical device company focused on an internal retractor for laproscopic procedures and other endoscopic surgical tools, closed a $2.6M Series A financing. Participants include Virginia Life Science Investments and Skywalker Ventures.http://onbiovc.com/virtual-ports-ltd-series-a-26m/feed/http://onbiovc.com/virtual-ports-ltd-series-a-26m/Alvine Pharmaceuticals, Inc.: Series A $21.5Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/k9OtmnQhT1E/I - Series AQ - 3Q09R - WESTX - AutoimmuneX - CeliacX - GIXX - CAarubensteinMon, 02 Nov 2009 13:13:01 PSThttp://onbiovc.com/?p=1463Alvine Pharmaceuticals (San Carlos, CA) a clinical-stage biopharmaceutical company focused on autoimmune related GI disease such as Celiac disease, closed a $21.5M financing bringing the total round to $47.5M. Participants include Panorama Capital, InterWest Partners, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures.

]]>Alvine Pharmaceuticals (San Carlos, CA) a clinical-stage biopharmaceutical company focused on autoimmune related GI disease such as Celiac disease, closed a $21.5M financing bringing the total round to $47.5M. Participants include Panorama Capital, InterWest Partners, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures.http://onbiovc.com/alvine-pharmaceuticals-inc-series-a-215m/feed/http://onbiovc.com/alvine-pharmaceuticals-inc-series-a-215m/